Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor

Journal of Clinical Investigation

Volumn 100, Issue 7, 1997, Pages 1804-1812

  Wu, Dafang ^a   Yang, Jing ^a   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid; Avidin; Insulin receptor; Monoclonal antibody

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN RECEPTOR; IODINE 125; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; STREPTAVIDIN;

ADOLESCENT; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSFORMATION; DRUG UPTAKE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0030930364     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119708     Document Type: Article

References (46)

1. Fischman, A.J., J.W. Babich, and H.W. Strauss. 1993. Peptide radiopharmaceuticals. J. Nucl. Med. 34:2253-2263.
2. 111In-octreotide scintigraphy in oncology. Metabolism. 41:83-86.
3. Reubi, J.C., L. Kvols, E. Krenning, and S.W.J. Lamberts. 1990. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism. 39:78-81.
4. Haldemann, A.R., H. Roseler, A. Barth, B. Waser, L. Geiger, N. Godoy, R. V. Markwalder, R.W. Seiler, M. Sulzer, and J.C. Reubi. 1995. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J. Nucl. Med. 36:403-410.
5. Pardridge, W.M., D. Triguero, J. Yang, and P.A. Cancilla. 1990. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253:884-891.
6. Tomlinson, B.E., G. Blessed, and M. Roth. 1970. Observations on the brains of demented old people. J. Neurol. Sci. 22:205-242.
7. Cummings, B.J., and C.W. Cotman. 1995. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 346: 1524-1528.
8. Glenner, G.G., and C.W. Wong. 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:885-890.
9. Masters, C.L., G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald, and K. Beyruther. 1985. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82:4245-4249.
10. Selkoe, D.J., C.R. Abraham, M.B. Podlisny, and L.K. Duffy. 1986. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J. Neurochem. 46:1820-1834.
11. Pardridge, W.M., H.V. Vinters, J. Yang, J. Eisenberg, T. Choi, W.W. Tourtellotte, V. Huebner, and J.E. Shively. 1987. Amyloid angiopathy of Alzheimer's disease: amino acid composition and partial sequence of a 4200 Dalton peptide isolated from cortical microvessels. J. Neurochem. 49:1394-1401.
12. Roher, A.E., J.D. Lowenson, S. Clarke, A.S. Woods, R.J. Cotter, E. Gowing, and M.J. Ball. 1993. β-Amyloid-1(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:10836-10840.
13. Kang, J., H.G. Lemaire, A. Unterbeck, J.M. Salbaum, C.L. Masters, K.H. Grezeschik, G. Malthaup, K. Beyreuther, and B. Muller-Hill. 1987. The precursor of Alzheimer disease amyloid A4 protein resembles a cell-surface receptor. Nature (Lond.). 325:733-736.
14. Stern, R.A., L. Otvos, Jr., J.O. Trojanowski, and V.M.-Y. Lee. 1989. Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease β-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. Amer. J Pathol. 134: 973-978.
15. Maagio, J.E., E.R. Stimson, J.R. Ghilardi, C.J. Allen, C.E. Dahl, D.C. Whitcomb, S.R. Vigna, H.V. Vinters, M.E. Labenski, and P.W. Mantyh. 1992. Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. USA. 89:5462-5466.
16. 1-40/vector complex. Proc. Natl. Acad. Sci. USA. 92:10227-10231.
17. Walker, L.C., C. Masters, K. Beyreuther, and D.L. Price. 1990. Amyloid in the brains of aged squirrel monkeys. Acta Neuropathol. 80:381-387.
18. Martin, L.J., S.S. Sangram, E.H. Koo, L.C. Cork, T.L. Dellovade, A. Weidemann, K. Beyreuther, C. Masters, and D.L. Price. 1991. Amyloid precursor protein in aged nonhuman primates. Proc. Natl. Acad. Sci. USA. 88:1461-1465.
19. Walker, L.C., D.L Price, M.L. Voytko, and D.B. Schenk. 1994. Labeling of cerebral amyloid in vivo with a monoclonal antibody. J. Neuropathol. Exp. Neurol. 53:377-383.
20. Gearing, M., G.W. Rebeck, B.T. Hyman, J. Tiggs, and S.S. Mirra. 1994. Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:9382-9386.
21. Pardridge, W.M., Y.S. Kang, J.L. Buciak, and J. Yang. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharmacol Res. 12:807-816.
22. Swindler, D.R., and J. Erwin, editors. 1986. Comparative Primate Biology. Alan R. Liss, New York.
23. Pardridge, W.M. 1995. Vector-mediated peptide drug delivery to the brain Advanced Drug Delivery Reviews (Elsevier) 15:109-146.
24. Prigent, S.A., K.K. Stanley, and K. Siddle. 1990. Identificatton of epitopes on the human insulin receptor reacting with rabbit polyclonal antisera and mouse monoclonal antibodies. J. Biol. Chem. 265:9970-9977.
25. Marsh, J.W. 1988. Antibody-mediated routing of diphtheria toxin in murine cells results in a highly efficacious immunotoxin. J. Biol. Chem. 263: 15993-15999.
26. Riddles, P.W., R.L. Blakeley, and B. Zerner. 1979. Ellman's reagent 5,5́-dithiobis(2-nitrobenzoic acid) - a reexamination. Anal. Biochem. 94:75-81.
27. Pardridge, W.M., R.J. Boado, and Y.S. King. 1995. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA. 92:5592-5596.
28. Yoshikawa, T., and W.M. Pardridge. 1992. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol. Exp. Ther. 263:897-903.
29. Pardridge, W.M., J. Eisenberg, and J. Yang. 1985. Human blood-brain barrier insulin receptor. J. Neurochem. 44:1771-1778.
30. Bickel, Y., T. Yoshikawa, E.M. Landaw, K.F. Faull, and W.M. Pardridge. 1993. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA. 90:2618-2622.
31. Jefferies, W.A., M.R. Brandon, S.V. Hunt, A.F. Williams, K.C. Gatter, and D.Y. Mason. 1984. Transferrin receptor on endothelium of brain capillaries. Nature (Lond.). 312:162-163.
32. Prior, R., D. D'Urso, R. Frank, I. Prikulis, S. Cleven, R. Ihl, and G. Pavlakovic. 1996. Selective binding of soluble Aβ1-40 and Aβ1-42 to a subset of senile plaques. Am. J. Pathol. 148:1749-1756.
33. Biere, A.L., B. Ostaszewski, E.R. Stimson, B.T. Hyman, J.E. Maggio, and D.J. Selkoe. 1996. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 271:32916-32922.
34. 111In-labeled nonspecific immunoglohulin scanning in the detection of focal infection. N. Engl. J. Med. 321: 935-940.
35. Zlokovic, B.V., J. Ghiso, J.B. Mackic, J.G. McComb, M.H. Weiss, and B. Frangione. 1993. Blood-brain barrier transport of circulating Alzheimer's amyloid β. Biochem. Biophys. Res. Commun. 197:1034-1040.
36. Ghersi-Egea, J.F., P.D. Gorevic, J. Ghiso, B. Frangione, C.S. Patlak, and J.D. Fenstermacher. 1996. Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67:880-883.
37. 68Ga]EDTA and positron emission tomography. J. Cereb. Blood Flow Metabol. 7:1-8.
38. 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport. 7:2607-2611.
39. Walus, L.R., W.M. Pardridge, R.M. Starzyk, and P.M. Friden. 1996. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier following conjugation to anti-transferrin receptor antibodies. J. Pharmacol. Exp. Ther. 277:1067-1075.
40. Jarrett, J.T., and P.T. Lansbury, Jr. 1993. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1055-1058.
41. Kuo, Y.M., M.R. Emmerling, C. Vigo-Pelfrey, T.C. Kasunic, J.B. Kirkpatrick, G.H. Murdoch, M.J. Ball, and A.E. Roher. 1996. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271: 4077-4081.
42. Nordstedt, C., J. Naslund, L.O. Tjernberg, A.R. Karlstrom, J. Thyberg, and L. Terenius. 1994. The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils. J. Biol. Chem. 269:30773-30776.
43. Shin, S.U., D. Wu, R. Ramanathan, W.M. Pardridge, and S.L. Morrison. 1997. Functional and pharmacokinetic properties of antibody/avidin fusion proteins. J. Immunol. 158:4797-1804.
44. Winter, G., and C. Milstein. 1991. Man-made antibodies. Nature (Lond.) 349:293-299.
45. Weiner, H.L. 1994. Oral tolerance. Proc. Natl. Acad. Sci. USA. 91: 10762-10765.
46. Samuel, A., G. Paganelli, R. Chiesa, F. Sudati, M. Calvitto, G. Melissano, A. Grossi, and F. Fazio. 1996. Detection of prosthetic vascular and graft infection using avidin/indium-111-biotin scintigraphy. J. Nucl. Med. 37:55-61.